Insulin resistance and cardiovascular outcomes in the ORIGIN trial

In the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (Clinicaltrials.gov: NCT000069784), titrated doses of basal insulin glargine targeting fasting normoglycaemia had a neutral effect on cardiovascular outcomes. The dose of insulin required to achieve normoglycaemia provides a unique measurement of each individual's resistance to insulin's action, and was therefore used to examine the link between insulin resistance and cardiovascular outcomes.

[1]  Michael E. Miller,et al.  Insulin Dose and Cardiovascular Mortality in the ACCORD Trial , 2015, Diabetes Care.

[2]  U. Lindblad,et al.  Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus, with effect modification by physical activity , 2015, European journal of preventive cardiology.

[3]  Jennifer G. Robinson,et al.  Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women’s Health Initiative , 2015, Circulation. Cardiovascular quality and outcomes.

[4]  E. Ferrannini,et al.  β-Cell function in type 2 diabetes. , 2014, Metabolism: clinical and experimental.

[5]  J. Gallacher,et al.  Glycated hemoglobin measurement and prediction of cardiovascular disease. , 2014, JAMA.

[6]  Qianchuan He,et al.  Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies. , 2013, The American journal of clinical nutrition.

[7]  H. Gerstein,et al.  Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. , 2013, The lancet. Diabetes & endocrinology.

[8]  L. Kuller,et al.  Insulin Resistance and Risk of Incident Heart Failure: Cardiovascular Health Study , 2013, Circulation. Heart failure.

[9]  Marc Evans,et al.  Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes , 2013, The Journal of clinical endocrinology and metabolism.

[10]  T. Stijnen,et al.  Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis , 2012, PloS one.

[11]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[12]  Regina M. Hardison,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[13]  R. Gans,et al.  Fasting insulin is a stronger cardiovascular risk factor in women than in men. , 2009, Atherosclerosis.

[14]  J. Danesh,et al.  Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. , 2007, European heart journal.

[15]  A. Avogaro,et al.  Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study , 2007, Stroke.

[16]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[17]  A. Häkkinen,et al.  Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. , 2000, Diabetes.

[18]  A. Folsom,et al.  Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Diabetes care.

[19]  A Mari,et al.  How to measure insulin sensitivity , 1998, Journal of hypertension.

[20]  R. DeFronzo,et al.  Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus , 1982, Diabetologia.

[21]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[22]  J. Shaw,et al.  HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study , 2009, Diabetologia.

[23]  H. Gerstein,et al.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.

[24]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[25]  P. Watson,et al.  Total body water volumes for adult males and females estimated from simple anthropometric measurements. , 1980, The American journal of clinical nutrition.